[181 Pages Report] The global continuous renal replacement therapy market size is projected to reach USD 1.7 billion by 2026 from USD 1.2 billion in 2021, at a CAGR of 7.3% during the forecast period. Various factors such as rise in worldwide prevalence of AKI, Growing number of ICU patients with AKI and increasing incidence of sepsis, and growing clinical advantage of CRRT over intermittent blood purification are factors likely to boost the growth of the market. Moreover, presence of well-established key players focusing on developing and commercializing technologically advanced and initiatives undertaken by government to increase the awareness about CRRT are likely to propel the market growth during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
The COVID-19 pandemic has significantly affected the CRRT market. The surge in the number of COVID cases, along with the rise in its severity rate, is likely to create a potential increase in the incidence of kidney damage. This makes AKI the next emerging healthcare concern after respiratory tract infections among patients with COVID-19.
Due to the pandemic, the demand for renal replacement fluids has increased significantly worldwide. The demand for RRT among patients with COVID-19 has increased fivefold in comparison to the historical US populations (4.9% as of 2020 VS. 0.9% earlier) (Source: American Society of Nephrology, 2021). According to an article published by the International Society of Nephrology 2020, countries such as China and Italy reported AKI rates as high as 29%. The early initiation of continuous renal replacement therapy (CRRT) is an important step to curbing the rising incidence of AKI due to the COVID-19 infection. However, owing to the rapid rise in the demand by healthcare systems, HD and PD exist as an alternative dialysis treatment in ICUs, which can have a negative impact on the growth of the CRRT market during this period.
The growing worldwide incidence of AKI/AKF is, therefore, expected to increase the demand for CRRT. According to the International Society of Nephrology (INR), an estimated 13.3 million cases of AKI are registered annually worldwide. This is anticipated to boost the adoption of continuous renal replacement therapy at a rapid rate. With the rapid growth in the geriatric population globally, the prevalence of kidney-related diseases is expected to increase significantly. This, in turn, is expected to propel the growth of the CRRT market at a significant rate during the forecast period.
As the population in emerging nations is price-sensitive, they prefer lower-priced products. Although the cost of CRRT in developing countries is high which makes these procedures are still unaffordable for a large portion of the population due to the low purchasing power. This limits the demand and uptake of CRRT in developing as well as developed countries.
Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the CRRT market. According to an article published by the Journal of Clinical and Diagnostic Research (JCDR) 2018, in a prospective observational study conducted in 100 critically ill patients In India, AKI was observed in 17.3 cases/1,000 persons. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers. Additionally, regulatory policies in the Asia Pacific region are more adaptive and business friendly due to the less-stringent data requirements. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further encourage CRRT product manufacturers to focus on the emerging markets
CRRT is a highly specialized and critical therapy that involves complex nursing care. Properly trained ICU nurses are required for the continuous assessment of indications, ensuring good vascular access, avoiding unnecessary interruptions, and preventing complications in patients during CRRT. However, currently, there is a dearth of registered nurses in ICU settings. Moreover the complexity associated with CRRT are likely to hinder the market growth.
The largest market share of this segment is attributed to factors such growing demand for dialysates to remove undesired solutes and restoring the electrolytes and acid-base balance in the blood along with presence of well established players with strong offerings in dialysates & replacement fluid
continuous venovenous hemodiafiltration (CVVHDF) is to have highest growth rate of the CRRT market, by modality during the forecast period.
The high growth rate of the CVVHDF segment can be attributed to its flexibility as compared to other CRRT modalities. The CVVHDF modality also combines the benefits of convection and diffusion for the removal of solutes, which is another major factor supporting its growth.
The increasing demand for invisible braces among adults due to large adult population base with AKI, increase in the hospitalization among adult population, and the large availability of CRRT system and disposables for adults undergoing CRRT procedure.
To know about the assumptions considered for the study, download the pdf brochure
Europe dominates CRRT market. Europen is gaining traction with the increasing incidence and prevalence of AKI. Moreover, strong foothold of major key players in the region, rising approval of CRRT products for multiple application across many European countries, and initiatives by government to increase the awareness about the advancements in renal therapy are likely to play a major role in fueling the growth of the CRRT market in the Europe.
The prominent players operating in the global market include Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US), Medites Pharma spol. s.r.o. (Czech Republic), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd. (China), Nipro Corporation (Japan), and Anjue Medical Equipment Co., Ltd. (China), among others.
Baxter International Inc.
Baxter is one of the global healthcare companies engaged in the development, manufacturing, and marketing of innovative products for the treatment of patients with infectious diseases, trauma, hemophilia, immune disorders, kidney diseases, and cancer. Baxter operates through two segmentsRenal and Hospital Products. The company offers a comprehensive portfolio of dialysis products, including products for PD, in-center HD, home HD, and CRRT, as well as additional dialysis services.
Baxter manufactures products in over 20 countries and serves patients and clinicians in around 100 countries. The company focuses mainly on organic growth (through new product development) to sustain its leading position in the global CRRT market. Moreover, during the COVID-19 pandemic, the company has received emergency FDA approval of hemofilter and CRRT systems for the treatment of AKI among COVID-19 patients. These factors are likely to play a significant role in increasing the companys brand value in the CRRT market during and post the pandemic
Report Metric |
Details |
Market Size Available for Years |
20192026 |
Base Year Considered |
2020 |
Forecast Period |
20212026 |
Forecast Units |
Value (USD Billion) |
Segments Covered |
Product, modality, age group and region. |
Geographies Covered |
North America (US & Canada), Europe (Germany, the UK, France, Italy, Spain, and RoE), APAC (Japan, China, Australia, South Korea India, and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA |
Companies Covered |
Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US), Medites Pharma spol. s.r.o. (Czech Republic), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd. (China), Nipro Corporation (Japan), and Anjue Medical Equipment Co., Ltd. (China), |
This research report categorizes the CRRT market based on product, modality, age group and region.
What are the drivers for the CRRT market?
The rise in the prevalence of AKI, growing number of ICU patients and presence of well-established key players focusing on developing and commercializing technologically advanced CRRT products are likely to propel the market growth during the forecast period.
Which segment provides the most opportunity for growth?
Among products, the dialysates and replacement fluids segment will show the most opportunity for growth.
Who are the leading vendors operating in this market?
Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Nipro Corporation (Japan).
Which region is expected to witness significant demand for CRRT in the coming years?
The Asia Pacific is the fastest-growing geographic segment in CRRT market, with a CAGR of 9.7% during the forecast period. This is attributed to the rising population base with AKI, increase in the healthcare expenditure, growing utilization of CRRT and emergence of key manufacturers in APAC CRRT market.
What is the COVID 19 impact on CRRT market in the coming years?
The recent COVID-19 global pandemic has also impacted the CRRT market. During the initial stage of COVID-19 (the first six months of the pandemic in 2020), many countries experienced a shortage of CRRT systems, with the demand outweighing the supply. The growing demand for renal replacement therapy increased the pressure on manufacturers to accelerate the delivery of CRRT systems and consumables in order to fulfill the need of the healthcare system. The early initiation of continuous renal replacement therapy (CRRT) is an important step to curbing the rising incidence of AKI due to the COVID-19 infection. However, owing to the rapid rise in the demand by healthcare systems, HD and PD exist as an alternative dialysis treatment in ICUs, which can have a negative impact on the growth of the CRRT market during this period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 25)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 29)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 USAGE-BASED MARKET ESTIMATION
FIGURE 4 ESTIMATION OF CRRT PROCEDURES
FIGURE 5 MARKET SIZE ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BASED ON PRODUCT UTILIZATION METHODOLOGY
FIGURE 6 MARKET SIZE ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BASED ON REVENUE MAPPING METHODOLOGY
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 39)
FIGURE 8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021 VS. 2026 (USD MILLION)
FIGURE 10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021 VS. 2026 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
4 PREMIUM INSIGHTS (Page No. - 43)
4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW
FIGURE 12 RISING PREVALENCE OF AKI AND GROWING AWARENESS ABOUT CRRT TO DRIVE MARKET GROWTH
4.2 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SHARE, BY AGE GROUP, 2021
FIGURE 13 ADULTS SEGMENT TO DOMINATE THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET IN 2021
4.3 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT AND COUNTRY
FIGURE 14 DIALYSATES AND REPLACEMENT FLUIDS ACCOUNT FOR THE LARGEST SHARE OF THE CRRT PRODUCTS MARKET IN THE APAC
FIGURE 15 APAC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (20212026)
5 MARKET OVERVIEW (Page No. - 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of acute kidney injury (AKI)
FIGURE 17 GLOBAL INCIDENCE OF AKI, 2010 VS. 2015 VS. 2020
TABLE 1 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2019 VS. 2050
5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
FIGURE 18 IMPACT OF ICU-ACQUIRED AKI IN THE US
5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
5.2.1.4 Technological advancements and new product launches
5.2.1.5 Growing prevalence of diabetes and hypertension
FIGURE 19 TOP 5 COUNTRIES WITH CHILDREN AND ADOLESCENTS WITH TYPE I DIABETES, 2019
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory guidelines in North America
5.2.2.2 High procedural cost of CRRT
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets in APAC and RoW
5.2.3.2 Increasing applications of CRRT
5.2.3.2.1 Evolution of CRRT from a simple renal replacement treatment to multi-organ support therapy
5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
5.2.3.3 Ongoing research to establish the safety and efficacy profile of CRRT
5.2.3.4 Development of CRRT systems for pediatric patients
5.2.3.4.1 The CARPEDIEM Project
5.2.3.5 Untapped growth opportunities in North America
5.2.4 CHALLENGES
5.2.4.1 High complexity of CRRT
5.2.4.2 Lack of standard treatment guidelines in developing nations
5.2.4.3 Shortage of trained ICU professionals in developing nations
5.2.4.4 Poor reimbursement scenario in developing countries
5.2.4.5 Lack of awareness about the benefits of CRRT
5.3 GLOBAL REGULATORY LANDSCAPE
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA PACIFIC
5.3.3.1 India
5.3.3.2 China
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.4 REST OF THE WORLD (ROW)
5.3.4.1 Brazil
5.3.4.2 Argentina
5.4 GLOBAL REIMBURSEMENT SCENARIO
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.3 ASIA PACIFIC
5.4.4 JAPAN
5.4.5 REST OF THE WORLD (ROW)
5.4.5.1 Brazil
5.4.5.2 Central America and the Caribbean
5.5 COVID-19 IMPACT ON THE CRRT MARKET
FIGURE 20 US: COVID-19 HOSPITALIZATION DATA FOR SPECIALIZED MEDICAL CONDITIONS IN ADULTS (AS OF APRIL 11, 2020)
5.6 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN OF THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
5.7 ECOSYSTEM COVERAGE
5.8 PRICING TREND ANALYSIS
TABLE 2 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
5.9 PORTERS FIVE FORCES ANALYSIS
TABLE 3 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PORTERS FIVE FORCES ANALYSIS
5.9.1 THREAT FROM NEW ENTRANTS
FIGURE 22 THREAT FROM NEW ENTRANTS
5.9.2 THREAT FROM SUBSTITUTES
FIGURE 23 THREAT FROM SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
FIGURE 24 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
FIGURE 25 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
FIGURE 26 INTENSITY OF COMPETITIVE RIVALRY
6 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT (Page No. - 69)
6.1 INTRODUCTION
TABLE 4 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
6.2 DIALYSATES & REPLACEMENT FLUIDS
6.2.1 RISING DEMAND FOR DIALYSATES HAS SUPPORTED MARKET GROWTH
TABLE 5 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 6 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY AGE GROUP, 20192026 (USD MILLION)
TABLE 7 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY REGION, 20192026 (USD MILLION)
6.3 DISPOSABLES
TABLE 8 DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 9 DISPOSABLES MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 10 DISPOSABLES MARKET, BY AGE GROUP, 20192026 (USD MILLION)
TABLE 11 DISPOSABLES MARKET, BY REGION, 20192026 (USD MILLION)
6.3.1 HEMOFILTERS
6.3.1.1 Hemofilters are widely adopted during CRRT procedures for the treatment of AKI
TABLE 12 HEMOFILTERS MARKET, BY REGION, 20192026 (USD MILLION)
TABLE 13 HEMOFILTERS MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 14 HEMOFILTERS MARKET, BY AGE GROUP, 20192026 (USD MILLION)
6.3.2 BLOODLINE SETS & TUBES
6.3.2.1 Established players are focusing on strengthening their bloodline sets and tubes product lines
TABLE 15 BLOODLINE SETS & TUBES MARKET, BY REGION, 20192026 (USD MILLION)
TABLE 16 BLOODLINE SETS & TUBES MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 17 BLOODLINE SETS & TUBES MARKET, BY AGE GROUP, 20192026 (USD MILLION)
6.3.3 OTHER DISPOSABLES
TABLE 18 OTHER DISPOSABLES MARKET, BY REGION, 20192026 (USD MILLION)
TABLE 19 OTHER DISPOSABLES MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 20 OTHER DISPOSABLES MARKET, BY AGE GROUP, 20192026 (USD MILLION)
6.4 CRRT SYSTEMS
6.4.1 INTRODUCTION OF ADVANCED PRODUCTS TO DRIVE THE DEMAND FOR CRRT SYSTEMS
TABLE 21 CRRT SYSTEMS MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 22 CRRT SYSTEMS MARKET, BY AGE GROUP, 20192026 (USD MILLION)
TABLE 23 CRRT SYSTEMS MARKET BY REGION, 20192026 (USD MILLION)
7 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY (Page No. - 80)
7.1 INTRODUCTION
TABLE 24 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 20192026 (USD MILLION)
7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION
7.2.1 WIDESPREAD ADOPTION OF CVVH IN THE TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET GROWTH
TABLE 25 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY REGION, 20192026 (USD MILLION)
7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION
7.3.1 CVVHDF IS USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
TABLE 26 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY REGION, 20192026 (USD MILLION)
7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS
7.4.1 THIS THERAPY IS MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES AS COMPARED TO OTHER CRRT MODALITIES
TABLE 27 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY REGION, 20192026 (USD MILLION)
7.5 SLOW CONTINUOUS ULTRAFILTRATION
7.5.1 SCUF DOES NOT USE DIALYSATES OR REPLACEMENT FLUIDS FOR THE REMOVAL OF EXCESS FLUID FROM THE BLOODSTREAM
TABLE 28 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY REGION, 20192026 (USD MILLION)
8 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP (Page No. - 86)
8.1 INTRODUCTION
TABLE 29 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 20192026 (USD MILLION)
8.2 ADULTS
8.2.1 ADULTS HOLD THE LARGEST SHARE OF THE MARKET BY AGE GROUP
TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY REGION, 20192026 (USD MILLION)
8.3 PEDIATRICS & NEONATES
8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO AID THE MARKET GROWTH DURING THE FORECAST PERIOD
TABLE 31 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS & NEONATES, BY REGION, 20192026 (USD MILLION)
9 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION (Page No. - 90)
9.1 INTRODUCTION
TABLE 32 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 20192026 (USD MILLION)
9.2 EUROPE
FIGURE 27 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
TABLE 33 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 34 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 35 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 36 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 37 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 20192026 (USD MILLION)
9.2.1 GERMANY
9.2.1.1 Germany is the largest market for continuous renal replacement therapy in Europe
TABLE 38 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 39 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.2.2 UK
9.2.2.1 Rising number of sepsis cases in the UK to support market growth
TABLE 40 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 41 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.2.3 FRANCE
9.2.3.1 France is the fastest-growing market for CRRT in Europe
TABLE 42 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 43 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.2.4 ITALY
9.2.4.1 Government initiatives to promote the awareness of CRRT for renal care to drive market growth
TABLE 44 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 45 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION
9.2.5 SPAIN
9.2.5.1 Favorable reimbursement scenario to favor market growth
TABLE 46 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 47 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.2.6 REST OF EUROPE
TABLE 48 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 49 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.3 NORTH AMERICA
TABLE 50 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 51 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 52 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 53 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 54 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 20192026 (USD MILLION)
9.3.1 US
9.3.1.1 Large number of AKI patients in the region to drive the market growth
TABLE 55 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 56 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.3.2 CANADA
9.3.2.1 High cost of CRRT as compared to IHD is negatively impacting market growth in Canada
TABLE 57 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 58 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 28 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
TABLE 59 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 60 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 61 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 62 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 63 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 20192026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Increasing use of CRRT to boost the market in Japan
TABLE 64 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 65 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.4.2 CHINA
9.4.2.1 Increasing prevalence of ESRD and AKI to boost the demand for CRRT
TABLE 66 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 67 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growing number of AKI patients and ICU admissions to support market growth
TABLE 68 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 69 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 The Australian government is taking various initiatives to increase the awareness of CRRT
TABLE 70 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 71 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.4.5 SOUTH KOREA
9.4.5.1 The country is witnessing an increasing number of patients receiving CRRT for the treatment of AKI
TABLE 72 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 73 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.4.6 REST OF ASIA PACIFIC
TABLE 74 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 75 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 76 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 77 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 78 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 79 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 80 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 20192026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Brazil holds the largest share in the Latin American CRRT market
TABLE 81 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 82 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 Large patient population and growing middle-class population to support market growth in Mexico
TABLE 83 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 84 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA
TABLE 85 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 86 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN THE MARKET GROWTH IN THE REGION
TABLE 87 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 20192026 (USD MILLION)
TABLE 88 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 89 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 20192026 (USD MILLION)
TABLE 90 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 20192026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 125)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CRRT MARKET
10.4 GLOBAL MARKET SHARE ANALYSIS (2020)
TABLE 91 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION
10.5 COMPETITIVE LEADERSHIP MAPPING
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
10.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 31 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020
10.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
10.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
TABLE 92 INDUSTRY FOOTPRINT OF COMPANIES
TABLE 93 REGIONAL FOOTPRINT OF COMPANIES
10.7.1.1 Continuous renal replacement therapy market: Product launches and regulatory approvals (January 2018 to May 2021)
TABLE 94 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
10.7.1.2 Continuous renal replacement therapy market: Deals (January 2018 to May 2021)
TABLE 95 KEY DEALS
10.7.1.3 Continuous renal replacement therapy market: Other developments (January 2018 to May 2021)
TABLE 96 KEY OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 137)
11.1 MAJOR PLAYERS
11.1.1 BAXTER INTERNATIONAL INC.
11.1.1.1 Business overview
TABLE 97 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: BAXTER INTERNATIONAL INC.
11.1.1.2 Products offered
TABLE 98 BAXTER INTERNATIONAL INC.: PRODUCT OFFERINGS
11.1.1.3 Recent developments
11.1.1.4 MnM view
11.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
11.1.2.1 Business overview
TABLE 99 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: FRESENIUS MEDICAL CARE AG & CO. KGAA
11.1.2.2 Products offered
TABLE 100 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
11.1.2.3 Recent developments
11.1.2.4 MnM view
11.1.3 NIKKISO CO., LTD.
11.1.3.1 Business overview
TABLE 101 NIKKISO CO., LTD.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: NIKKISO CO., LTD.
11.1.3.2 Products offered
TABLE 102 NIKKISO CO., LTD.: PRODUCT OFFERINGS
11.1.3.3 MnM view
11.1.4 B. BRAUN MELSUNGEN AG
11.1.4.1 Business overview
TABLE 103 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG
11.1.4.2 Products offered
TABLE 104 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
11.1.4.3 Recent developments
11.1.4.4 MnM view
11.1.5 MEDTRONIC PLC
11.1.5.1 Business overview
TABLE 105 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: MEDTRONIC PLC
11.1.5.2 Products offered
TABLE 106 MEDTRONIC PLC: PRODUCT OFFERINGS
11.1.5.3 Recent developments
11.1.6 ASAHI KASEI CORPORATION
11.1.6.1 Business overview
TABLE 107 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: ASAHI KASEI CORPORATION
11.1.6.2 Products offered
TABLE 108 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
11.1.7 TORAY MEDICAL CO., LTD.
11.1.7.1 Business overview
TABLE 109 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: TORAY MEDICAL CO., LTD.
11.1.7.2 Products offered
TABLE 110 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
11.1.8 NIPRO CORPORATION
11.1.8.1 Business overview
TABLE 111 NIPRO CORPORATION: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: NIPRO CORPORATION
11.1.8.2 Products offered
TABLE 112 NIPRO CORPORATION: PRODUCT OFFERINGS
11.1.8.3 Recent developments
11.1.9 INFOMED SA
11.1.9.1 Business overview
TABLE 113 INFOMED SA: BUSINESS OVERVIEW
11.1.9.2 Products offered
TABLE 114 INFOMED SA: PRODUCT OFFERINGS
11.1.9.3 Recent developments
11.1.9.4 MnM view
11.1.10 MEDICA SPA
11.1.10.1 Business overview
TABLE 115 MEDICA SPA: BUSINESS OVERVIEW
11.1.10.2 Products offered
TABLE 116 MEDICA SPA: PRODUCT OFFERINGS
11.1.11 MEDITES PHARMA SPOL. S.R.O
11.1.11.1 Business overview
TABLE 117 MEDITES PHARMA SPOL. S.R.O: BUSINESS OVERVIEW
11.1.11.2 Products offered
TABLE 118 MEDITES PHARMA SPOL. S.R.O: PRODUCT OFFERINGS
11.1.12 MEDICAL COMPONENTS, INC.
11.1.12.1 Business overview
TABLE 119 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
11.1.12.2 Products offered
TABLE 120 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
11.1.13 SWS HEMODIALYSIS CARE CO. LTD.
11.1.13.1 Business overview
TABLE 121 SWS HEMODIALYSIS CARE CO. LTD.: BUSINESS OVERVIEW
11.1.13.2 Products offered
TABLE 122 SWS HEMODIALYSIS CARE CO. LTD.: PRODUCT OFFERINGS
11.1.13.3 Recent developments
11.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
11.1.14.1 Business overview
TABLE 123 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
11.1.14.2 Products offered
TABLE 124 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
11.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
11.1.15.1 Business overview
TABLE 125 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
11.1.15.2 Products offered
TABLE 126 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
11.2 EMERGING PLAYERS
11.2.1 KIMAL
11.2.2 JIANGXI SANXIN MEDTEC CO., LTD.
11.2.3 ALLMED MEDICAL PRODUCTS CO., LTD.
11.2.4 DIALCO MEDICAL INC.
11.2.5 BROWNDOVE HEALTHCARE PVT. LTD.
12 APPENDIX (Page No. - 174)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the Continuous Renal Replacement Therapy (CRRT) market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, regulatory bodies, and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), American Society Nephrology (ASN), American Association of Kidney Patients (AAKP), European Renal Association were referred to identify and collect information for the CRRTmarket study.
The CRRT market comprises several stakeholders such as manufacturers Of CRRT machine, CRRT disposables, dialysates and replacement fluids, market research and consulting firms. The demand side of this market is characterized by the increasing AKI, growing awareness of CRRT, and increased in number of players in the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the CRRT market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall size of the global CRRT market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
With the given market data, MarketsandMarkets offers customizations as per your companys specific needs. The following customization options are available for the global CRRT market report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
Growth opportunities and latent adjacency in Continuous Renal Replacement Therapy (CRRT) Market